Development_NP and_CC Evaluation_NP of_IN Rapid_NP Urinary_NP Antigen_NP Detection_NP Tests_NP for_IN Diagnosis_NN of_IN Penicilliosis_NP Marneffei_NP Penicilliosis_NN ,_, caused_VBN by_IN the_DT dimorphic_JJ fungus_NN Penicillium_NP marneffei_NP ,_, is_VBZ an_DT important_JJ opportunistic_JJ systemic_JJ fungal_JJ infection_NN affecting_VBG immunocompromised_JJ individuals_NNS living_VBG in_IN areas_NNS where_WRB penicilliosis_NN is_VBZ endemic_JJ ._SENT We_PP have_VBP demonstrated_VBN previously_RB that_IN a_DT urinary_JJ enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) with_IN purified_VBN rabbit_NN polyclonal_JJ antibody_NN against_IN killed_VBN whole-fission-form_NN arthroconidia_NN of_IN P._NP marneffei_NP was_VBD specific_JJ and_CC highly_RB sensitive_JJ for_IN the_DT diagnosis_NN of_IN penicilliosis_NN ._SENT In_IN this_DT study_NN ,_, a_DT dot_NN blot_NN ELISA_NP and_CC a_DT latex_NN agglutination_NN (_( LA_NP )_) test_NN were_VBD developed_VBN with_IN the_DT same_JJ polyclonal_JJ antibody_NN and_CC compared_VBN with_IN the_DT ELISA_NP for_IN the_DT detection_NN of_IN P._NP marneffei_NP urinary_JJ antigen_NN ._SENT Urine_NN specimens_NNS from_IN 37_CD patients_NNS with_IN culture-proven_JJ penicilliosis_NN and_CC 300_CD controls_NNS (_( 52_CD healthy_JJ subjects_NNS and_CC 248_CD hospitalized_VBN patients_NNS without_IN penicilliosis_NN )_) were_VBD tested_VBN ._SENT Antigen_NN was_VBD detected_VBN in_IN urine_NN from_IN all_DT 37_CD (_( 100_CD %_NN )_) penicilliosis_NN patients_NNS by_IN the_DT LA_NP test_NN ,_, 35_CD (_( 94.6_CD %_NN )_) penicilliosis_NN patients_NNS by_IN the_DT dot_NN blot_NN ELISA_NP ,_, and_CC 36_CD (_( 97.3_CD %_NN )_) penicilliosis_NN patients_NNS by_IN the_DT ELISA_NP ._SENT False-positive_JJ results_NNS were_VBD found_VBN by_IN the_DT three_CD assays_NNS for_IN 2_CD (_( 0.7_CD %_NN )_) ,_, 8_CD (_( 2.7_CD %_NN )_) ,_, and_CC 6_CD (_( 2_CD %_NN )_) of_IN 300_CD controls_NNS ,_, respectively_RB ._SENT The_DT overall_JJ sensitivities_NNS of_IN the_DT diagnostic_JJ tests_NNS were_VBD as_RB follows_VBZ :_: dot_NN blot_NN ELISA_NP ,_, 94.6_CD %_NN ;_: ELISA_NP ,_, 97.3_CD %_NN ;_: and_CC LA_NP test_NN ,_, 100_CD %_NN (_( specificities_NNS ,_, 97.3_CD ,_, 98_CD ,_, and_CC 99.3_CD %_NN ,_, respectively_RB )_) ._SENT The_DT LA_NP test_NN is_VBZ simple_JJ ,_, robust_JJ ,_, rapid_JJ ,_, and_CC convenient_JJ and_CC should_MD prove_VB to_TO be_VB an_DT important_JJ addition_NN to_TO the_DT existing_JJ diagnostic_JJ tests_NNS for_IN penicilliosis_NN ._SENT Penicilliosis_NN ,_, caused_VBN by_IN the_DT dimorphic_JJ fungus_NN Penicillium_NP marneffei_NP ,_, is_VBZ increasingly_RB common_JJ in_IN southeast_JJ Asia_NP ,_, particularly_RB Thailand_NP ._SENT Human_JJ infection_NN with_IN P._NP marneffei_NP was_VBD rare_JJ prior_RB to_TO the_DT AIDS_NP epidemic_NN in_IN this_DT area_NN ,_, but_CC the_DT number_NN of_IN cases_NNS has_VBZ since_RB risen_VBN dramatically_RB ._SENT In_IN Thailand_NP ,_, penicilliosis_NN is_VBZ a_DT major_JJ opportunistic_JJ infection_NN in_IN AIDS_NP patients_NNS ,_, particularly_RB in_IN the_DT north_NN of_IN the_DT country_NN ._SENT Infection_NN with_IN P._NP marneffei_NP usually_RB presents_VBZ as_IN a_DT disseminated_VBN and_CC progressive_JJ illness_NN in_IN patients_NNS with_IN CD4_NP counts_VBZ below_IN 100_CD ,_, with_IN fever_NN ,_, anemia_NN ,_, leukopenia_NN ,_, weight_NN loss_NN ,_, diarrhea_NN ,_, cough_NN ,_, massive_JJ hepatosplenomegaly_NN ,_, generalized_VBN lymphadenopathy_NN ,_, and_CC characteristic_JJ multiple_JJ umbilicated_JJ skin_NN lesions_NNS particularly_RB affecting_VBG the_DT face_NN and_CC upper_JJ body_NN ._SENT Penicilliosis_NN is_VBZ fatal_JJ if_IN it_PP is_VBZ left_RB untreated_JJ but_CC responds_VBZ well_RB to_TO antifungal_JJ agents_NNS such_JJ as_IN amphotericin_NP B_NP and_CC itraconazole_NN ._SENT A_DT presumptive_JJ diagnosis_NN of_IN P._NP marneffei_NP infection_NN is_VBZ made_VBN on_IN clinical_JJ grounds_NNS in_IN conjunction_NN with_IN microscopic_JJ identification_NN of_IN characteristic_JJ septate_JJ yeast_NN cells_NNS in_IN smears_NNS of_IN skin_NN lesions_NNS ,_, blood_NN ,_, or_CC bone_NN marrow_NN ._SENT Definitive_JJ diagnosis_NN relies_VBZ on_IN the_DT isolation_NN of_IN P._NP marneffei_NP by_IN culture_NN from_IN clinical_JJ specimens_NNS ._SENT However_RB ,_, cultures_NNS often_RB require_VBP at_IN least_JJS 3_CD days_NNS of_IN incubation_NN before_IN definitive_JJ identification_NN of_IN the_DT fungus_NN is_VBZ possible_JJ ._SENT Identification_NN of_IN P._NP marneffei_NNS by_IN means_NNS of_IN histological_JJ or_CC immunohistochemical_JJ techniques_NNS and_CC exoantigen_NN tests_NNS has_VBZ been_VBN reported_VBN ._SENT These_DT tests_NNS are_VBP specific_JJ ,_, but_CC time-consuming_JJ and_CC laborious_JJ ._SENT Serological_JJ methods_NNS have_VBP also_RB been_VBN developed_VBN ._SENT Detection_NN of_IN antibodies_NNS to_TO P._NP marneffei_NNS by_IN use_NN of_IN an_DT immunodiffusion_NN test_NN ,_, an_DT indirect_JJ fluorescent-antibody_NN technique_NN ,_, and_CC an_DT enzyme-linked_JJ immunosorbent_JJ assay_NN (_( ELISA_NP )_) antibody_NN detection_NN test_NN have_VBP each_DT been_VBN described_VBN ,_, but_CC these_DT tests_NNS ,_, while_IN specific_JJ ,_, are_VBP less_RBR sensitive_JJ than_IN culture_NN ._SENT Antigen_NN detection_NN tests_NNS have_VBP also_RB been_VBN studied_VBN ._SENT We_PP have_VBP shown_VBN previously_RB that_IN P._NP marneffei_NP antigen_NN can_MD be_VB detected_VBN at_IN high_JJ titers_NNS in_IN urine_NN by_IN ELISA_NP with_IN a_DT fluorescein_NN isothiocyanate_NN (FITC)-labeled_JJ purified_VBN rabbit_NN polyclonal_JJ hyperimmune_NN immunoglobulin_NN G_NP (_( IgG_NP )_) ._SENT This_DT test_NN is_VBZ highly_RB sensitive_JJ and_CC specific_JJ ._SENT We_PP now_RB report_VBP on_IN the_DT development_NN of_IN a_DT simplified_VBN dot_NN blot_NN ELISA_NP and_CC a_DT latex_NN agglutination_NN (_( LA_NP )_) test_NN for_IN detecting_VBG P._NP marneffei_NP antigenuria_NP by_IN using_VBG the_DT polyclonal_JJ anti-P_NN ._SENT marneffei_NN antibody_NN used_VBN previously_RB in_IN the_DT urinary_JJ antigen_NN ELISA_NP ._SENT The_DT dot_NN blot_NN ELISA_NP and_CC LA_NP tests_NNS were_VBD clinically_RB evaluated_VBN in_IN an_DT area_NN of_IN northeast_JJ Thailand_NP where_WRB penicilliosis_NN is_VBZ endemic_NN and_CC were_VBD compared_VBN with_IN the_DT urinary_JJ antigen_NN ELISA_NP for_IN the_DT diagnosis_NN of_IN penicilliosis_NN ._SENT Patients_NNS and_CC urine_NN samples_NNS ._SENT |_SYM The_DT study_NN was_VBD conducted_VBN between_IN June_NP 1995_CD and_CC July_NP 2000_CD ._SENT Adult_NN patients_NNS with_IN suspected_VBN or_CC confirmed_VBN penicilliosis_NN admitted_VBN to_TO Sappasitprasong_NP Hospital_NP ,_, Ubon_NP Ratchathani_NP ,_, northeast_JJ Thailand_NP ,_, were_VBD included_VBN in_IN the_DT study_NN ._SENT All_DT patients_NNS were_VBD seen_VBN by_IN a_DT member_NN of_IN the_DT study_NN team_NN ,_, and_CC full_JJ clinical_JJ details_NNS were_VBD recorded_VBN on_IN a_DT standard_JJ form_NN ._SENT Routine_JJ hematological_JJ and_CC biochemical_JJ tests_NNS were_VBD performed_VBN ,_, and_CC the_DT patients_NNS were_VBD evaluated_VBN for_IN the_DT presence_NN of_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) antibody_NN when_WRB indicated_VBN ._SENT The_DT diagnosis_NN of_IN penicilliosis_NN was_VBD confirmed_VBN by_IN isolation_NN of_IN P._NP marneffei_NP from_IN blood_NN ,_, urine_NN ,_, lymph_NN node_NN biopsy_NN ,_, and_CC liver_JJR aspirate_JJ specimens_NNS or_CC throat_NN or_CC skin_NN lesion_NN swab_NN specimens_NNS ;_: a_DT presumptive_JJ diagnosis_NN was_VBD made_VBN by_IN direct_JJ identification_NN of_IN septate_JJ yeast_NN cells_NNS in_IN stained_VBN smears_NNS made_VBN from_IN appropriate_JJ clinical_JJ specimens_NNS ._SENT A_DT total_NN of_IN 37_CD urine_NN samples_NNS were_VBD obtained_VBN on_IN admission_NN from_IN HIV-positive_JJ patients_NNS confirmed_VBD to_TO have_VB penicilliosis_NN ._SENT Control_NN urine_NN samples_NNS were_VBD obtained_VBN from_IN healthy_JJ individuals_NNS (_( n_NN =_SYM 52_CD )_) ;_: HIV-seropositive_JJ patients_NNS with_IN other_JJ fungal_JJ infections_NNS (_( total_JJ ,_, n_NN =_SYM 34_CD ;_: cryptococcosis_NN ,_, n_NN =_SYM 31_CD ;_: histoplasmosis_NN ,_, n_NN =_SYM 1_CD ;_: candidiasis_NN ,_, n_NN =_SYM 2_CD )_) ;_: patients_NNS with_IN melioidosis_NN (_( n_NN =_SYM 168_CD )_) ,_, other_JJ bacterial_JJ causes_NNS of_IN septicemia_NN (_( n_NN =_SYM 12_CD )_) ,_, and_CC other_JJ bacterial_JJ infections_NNS (_( n_NN =_SYM 7_CD )_) ;_: and_CC inpatients_NNS for_IN whom_WP all_DT cultures_NNS were_VBD negative_JJ (_( n_NN =_SYM 27_CD )_) ._SENT All_DT urine_NN samples_NNS were_VBD stored_VBN at_IN -30C_NN and_CC thawed_VBD only_RB at_IN the_DT time_NN of_IN testing_NN ._SENT Antigen_NN preparation_NN ._SENT |_SYM Antigen_NN was_VBD prepared_VBN as_IN described_VBN previously_RB ._SENT Briefly_RB ,_, killed_VBD fission-form_NN arthroconidia_NN of_IN a_DT clinical_JJ isolate_NN of_IN P._NP marneffei_NP (_( grown_VBN in_IN brain_NN heart_NN infusion_NN broth_NN )_) were_VBD used_VBN to_TO immunize_VB rabbits_NNS and_CC as_IN the_DT control_NN antigen_NN for_IN the_DT ELISA_NP ,_, dot_NN blot_NN ELISA_NP ,_, and_CC LA_NP test_NN ._SENT Anti-P_NN ._SENT marneffei_NP IgG_NP preparation_NN ._SENT |_SYM Hyperimmune_NP rabbit_NN sera_NN with_IN antibodies_NNS against_IN P._NP marneffei_NP were_VBD prepared_VBN as_IN described_VBN previously_RB ._SENT The_DT purified_VBN IgG_NP fraction_NN was_VBD used_VBN in_IN the_DT ELISA_NP ,_, dot_NN blot_NN ELISA_NP ,_, and_CC LA_NP test_NN ._SENT ELISA_NP ._SENT |_SYM Urinary_NP P._NP marneffei_NP antigen_NN was_VBD detected_VBN by_IN a_DT sandwich_NN ELISA_NP ,_, as_RB described_VBN previously_RB ._SENT The_DT ELISA_NP uses_VBZ a_DT polyclonal_JJ anti-P_NN ._SENT marneffei_NN antibody_NN conjugated_VBN to_TO FITC_NP and_CC an_DT anti-FITC_NN antibody_NN amplification_NN system_NN ._SENT A_DT titer_NN of_IN 1:40_CD or_CC greater_JJR was_VBD considered_VBN a_DT positive_JJ result_NN for_IN P._NP marneffei_NP antigen_NN ._SENT Dot_NN blot_NN ELISA_NP ._SENT |_SYM Optimal_NP incubation_NN conditions_NNS and_CC reagent_NN concentrations_NNS for_IN the_DT dot_NN blot_NN ELISA_NP were_VBD determined_VBN by_IN checkerboard_NN titration_NN ._SENT Urine_NN samples_NNS were_VBD boiled_VBN for_IN 6_CD min_NN and_CC centrifuged_VBN at_IN 5,000_CD x_NN g_NN for_IN 6_CD min_NN to_TO remove_VB any_DT precipitate_NN before_IN testing_NN ._SENT A_DT 2-mul_JJ aliquot_NN of_IN each_DT urine_NN sample_NN was_VBD then_RB dotted_VBN onto_IN an_DT 11.5-cm2_JJ nitrocellulose_NN (_( NC_NP )_) membrane_NN sheet_NN (_( Bio-Rad_NP Laboratories_NP ,_, Richmond_NP ,_, Calif._NP )_) at_IN 1.3-cm_NN intervals_NNS ._SENT The_DT blotted_VBN NC_NP sheet_NN was_VBD dried_VBN at_IN 37C_JJ for_IN 30_CD min_NN and_CC subsequently_RB blocked_VBN with_IN blocking_VBG buffer_NN consisting_VBG of_IN 2_CD %_NN bovine_JJ serum_NN albumin_NN (_( Sigma_NP Chemical_NP Company_NP ,_, St._NP Louis_NP ,_, Mo._NP )_) in_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) containing_VBG 0.02_CD %_NN Tween_NP 20_CD (_( PBS-T_NP )_) for_IN 20_CD min_NN at_IN room_NN temperature_NN ._SENT After_IN the_DT NC_NP sheet_NN was_VBD washed_VBN with_IN PBS-T_NP ,_, it_PP was_VBD incubated_VBN with_IN purified_VBN rabbit_NN anti-P_NN ._SENT marneffei_NP IgG_NP diluted_VBD 1:500_CD in_IN blocking_VBG buffer_NN for_IN 1_CD h_NN at_IN room_NN temperature_NN ._SENT The_DT sheet_NN was_VBD washed_VBN once_RB and_CC was_VBD incubated_VBN for_IN 1_CD h_NN at_IN room_NN temperature_NN with_IN alkaline_JJ phosphatase-conjugated_JJ swine_NN anti-rabbit_NN immunoglobulin_NN (_( Dakopatt_NP ,_, Copenhagen_NP ,_, Denmark_NP )_) diluted_VBD 1:500_CD in_IN blocking_VBG buffer_NN ._SENT After_IN further_JJR washing_NN ,_, the_DT NC_NP sheet_NN was_VBD immersed_VBN in_IN substrate_NN solution_NN (_( freshly_RB prepared_VBN by_IN mixing_VBG 330_CD mul_NN of_IN nitro_NP blue_JJ tetrazolium_NN [_SYM 10_CD mg/ml_NN ]_SYM with_IN 33_CD mul_NN of_IN 5-bromo-4-chloro-3-indolyl_JJ phosphate_NN p-toluine_JJ salt_NN [_SYM 50_CD mg/ml_NN of_IN 100_CD %_NN dimethyl_NN formamide_NN ;_: Sigma_NP ]_SYM and_CC diluted_VBN to_TO 10_CD ml_NN with_IN substrate_NN buffer_NN [_SYM 0.1_CD M_NP Tris_NP buffer_NN {_( pH_NN 9.5_CD }_) containing_VBG 100_CD mM_NP sodium_NN chloride_NN and_CC 5_CD mM_NP magnesium_NN chloride_NN ]_SYM )_) and_CC then_RB incubated_VBN for_IN 10_CD min_NN at_IN room_NN temperature_NN to_TO allow_VB color_JJ development_NN before_IN it_PP was_VBD rinsed_VBN with_IN stopping_VBG buffer_NN (_( 0.02_CD M_NP Tris_NP buffer_NN containing_VBG 0.2_CD M_NP disodium_NN EDTA_NP )_) ._SENT The_DT NC_NP sheet_NN was_VBD then_RB washed_VBN with_IN distilled_JJ water_NN and_CC air_NN dried_VBD ._SENT A_DT purple_JJ dot_NN indicated_VBD a_DT positive_JJ reaction_NN ,_, and_CC a_DT pale_JJ brown_JJ dot_NN or_CC a_DT clear_JJ area_NN was_VBD read_VBN as_IN a_DT negative_JJ reaction_NN ._SENT The_DT same_JJ controls_NNS used_VBN in_IN the_DT ELISA_NP were_VBD included_VBN in_IN this_DT assay_NN ._SENT All_DT urine_NN samples_NNS and_CC controls_NNS were_VBD tested_VBN in_IN duplicate_NN ._SENT Preparation_NN of_IN LA_NP test_NN ._SENT |_SYM A_DT purified_VBN IgG_NP fraction_NN of_IN the_DT pooled_JJ rabbit_NN immune_JJ serum_NN with_IN antibodies_NNS against_IN P._NP marneffei_NP was_VBD adjusted_VBN to_TO a_DT concentration_NN of_IN 15_CD to_TO 20_CD mg/ml_NN and_CC used_VBN to_TO coat_VB the_DT test_NN latex_NN particles_NNS ._SENT A_DT 1_CD %_NN suspension_NN of_IN latex_NN polystyrene_NN beads_NNS (_( diameter_NN ,_, 0.6_CD mum_NN ;_: Sigma_NP )_) in_IN glycine-buffered_JJ saline_NN (_( pH_NN 8.2_CD )_) was_VBD sensitized_VBN by_IN mixing_VBG of_IN the_DT beads_NNS with_IN purified_VBN rabbit_NN anti-P_NN ._SENT marneffei_NP IgG_NP at_IN 37C_JJ for_IN 2_CD h_NN before_IN the_DT addition_NN of_IN bovine_JJ serum_NN albumin_NN to_TO a_DT final_JJ concentration_NN of_IN 0.5_CD %_NN (_( wt/vol_NN )_) ._SENT The_DT optimal_JJ quantity_NN of_IN immunoglobulin_NN used_VBN was_VBD the_DT highest_JJS dilution_NN that_WDT produced_VBD a_DT clear_JJ agglutination_NN with_IN the_DT highest_JJS reactive_JJ dilution_NN of_IN P._NP marneffei_NP culture_NN suspension_NN (_( starting_VBG at_IN a_DT concentration_NN of_IN 106_CD yeast_NN cells/ml_NN in_IN a_DT box_NN titration_NN )_) ._SENT Control_NN latex_NN particles_NNS were_VBD coated_VBN with_IN purified_VBN ,_, pooled_VBN normal_JJ rabbit_NN IgG_NP ._SENT The_DT suspensions_NNS were_VBD stored_VBN at_IN 4C_JJ and_CC brought_VBN to_TO room_NN temperature_NN before_IN use_NN ._SENT LA_DT method_NN ._SENT |_SYM All_DT urine_NN samples_NNS were_VBD boiled_VBN for_IN 6_CD min_NN ,_, cooled_VBN ,_, and_CC centrifuged_VBD at_IN 5,000_CD x_NN g_NN for_IN 6_CD min_NN to_TO remove_VB any_DT precipitate_NN before_IN testing_NN ._SENT The_DT LA_NP test_NN was_VBD performed_VBN by_IN placing_VBG 15_CD mul_NN of_IN test_NN and_CC control_NN latex_NN suspensions_NNS on_IN a_DT clean_JJ glass_NN slide_NN ._SENT Five_CD microliters_NNS of_IN urine_NN was_VBD added_VBN to_TO the_DT latex_NN particles_NNS ._SENT After_IN the_DT components_NNS were_VBD mixed_VBN ,_, the_DT slide_NN was_VBD rocked_VBN gently_RB for_IN 3_CD min_NN ._SENT Agglutination_NN with_IN the_DT test_NN latex_NN but_CC not_RB the_DT control_NN latex_NN indicated_VBD a_DT positive_JJ result_NN ,_, while_IN a_DT lack_NN of_IN agglutination_NN with_IN either_DT latex_NN indicated_VBD a_DT negative_JJ result_NN ._SENT Agglutination_NN with_IN both_CC the_DT test_NN and_CC the_DT control_NN latexes_NNS was_VBD interpreted_VBN as_IN a_DT nonspecific_JJ (_( negative_JJ )_) reaction_NN ._SENT Fungal_JJ and_CC bacterial_JJ strains_NNS ._SENT |_SYM To_TO evaluate_VB the_DT specificities_NNS of_IN the_DT dot_NN blot_NN ELISA_NP and_CC the_DT LA_NP method_NN ,_, Merthiolate-killed_JJ brain_NN heart_NN infusion_NN broth_NN cultures_NNS (_( 20-ml_JJ broth_NN volumes_NNS )_) of_IN various_JJ fungal_JJ species_NNS (_( Penicillium_NP griseofulvum_NN ATCC_NP 48166_CD ,_, Penicillium_NP chrysogenum_NN ATCC_NP 9480_CD ,_, Penicillium_NP notatum_NN ATCC_NP 9478_CD ,_, Aspergillus_NP terreus_NN ,_, Aspergillus_NP fumigatus_NN BCC_NP 123_CD ,_, Aspergillus_NP flavus_NN BCC_NP 235_CD ,_, Histoplasma_NN capsulatum_NN var._JJ capsulatum_NN ,_, Candida_NP albicans_NP [_SYM two_CD strains_NNS ]_SYM ,_, Candida_NP kefyr_NP ,_, Cryptococcus_NP neoformans_NP var._NP neoformans_NP ,_, Cryptococcus_NP neoformans_NP var._NP gattii_NP ,_, Sporothrix_NP schenkii_NP ,_, and_CC Trichosporon_NP beigelii_NNS )_) were_VBD tested_VBN at_IN various_JJ concentrations_NNS ,_, together_RB with_IN seven_CD clinical_JJ strains_NNS of_IN P._NP marneffei_NP (_( three_CD hyphal_JJ forms_NNS and_CC four_CD yeast-like_JJ forms_NNS )_) ._SENT The_DT cultures_NNS were_VBD incubated_VBN for_IN 48_CD h_NN at_IN 37C_JJ (_( Candida_NP ,_, Cryptococcus_NP ,_, and_CC Trichosporon_NP )_) ,_, 4_CD days_NNS at_IN 37C_JJ (_( P._NP marneffei_NP yeast_NN phase_NN )_) ,_, or_CC 4_CD days_NNS at_IN room_NN temperature_NN (_( P._NP marneffei_NP hyphal_JJ form_NN and_CC all_DT other_JJ species_NN )_) ._SENT The_DT final_JJ yeast_NN cell_NN or_CC spore_NN counts_NNS in_IN broth_NN were_VBD determined_VBN with_IN a_DT counting_VBG chamber_NN ._SENT Following_VBG subculture_NN to_TO ensure_VB purity_NN ,_, the_DT organisms_NNS were_VBD killed_VBN by_IN overnight_JJ incubation_NN with_IN Merthiolate_JJ (_( final_JJ Merthiolate_JJ concentration_NN ,_, 0.2_CD %_NN )_) ._SENT Appropriate_JJ test_NN dilutions_NNS were_VBD then_RB made_VBN in_IN sterile_JJ urine_NN (_( boiled_VBN )_) from_IN a_DT healthy_JJ human_JJ volunteer_NN ._SENT Strains_NNS of_IN Burkholderia_NP pseudomallei_NP (_( strain_NN 203a_NP )_) ,_, Salmonella_NP enterica_NP serovar_NP Enteritidis_NP ,_, and_CC Staphylococcus_NP aureus_NN ,_, which_WDT are_VBP common_JJ causes_NNS of_IN systemic_JJ infection_NN in_IN Ubon_NP Ratchathani_NP ,_, were_VBD also_RB tested_VBN ,_, in_IN addition_NN to_TO a_DT strain_NN of_IN S._NP enterica_NP serovar_NP Typhi_NP ._SENT These_DT fungal_JJ and_CC bacterial_JJ control_NN strains_NNS were_VBD all_RB as_RB described_VBN previously_RB ._SENT All_DT samples_NNS were_VBD tested_VBN in_IN duplicate_NN ,_, and_CC each_DT test_NN was_VBD repeated_VBN three_CD times_NNS ._SENT Statistical_JJ analysis_NN ._SENT |_SYM Data_NP were_VBD analyzed_VBN with_IN SPSS_NP for_IN Windows_NP (_( version_NN 9.0_CD ;_: SPSS_NP Inc._NP ,_, Chicago_NP ,_, Ill._NP )_) computer_NN software_NN ._SENT Quantitative_JJ variables_NNS with_IN a_DT nonnormal_JJ distribution_NN were_VBD expressed_VBN as_IN medians_NNS and_CC ranges_NNS ._SENT Qualitative_JJ variables_NNS were_VBD expressed_VBN as_IN frequencies_NNS and_CC percentages_NNS ._SENT The_DT sensitivities_NNS (_( proportions_NNS of_IN positive_JJ samples_NNS correctly_RB identified_VBN by_IN the_DT test_NN )_) and_CC the_DT specificities_NNS (_( proportions_NNS of_IN negative_JJ samples_NNS correctly_RB identified_VBN by_IN the_DT test_NN )_) of_IN the_DT dot_NN blot_NN ELISA_NP and_CC LA_NP test_NN were_VBD compared_VBN with_IN those_DT of_IN the_DT ELISA_NP and_CC evaluated_VBN by_IN using_VBG the_DT method_NN of_IN Galen_NP ._SENT The_DT sensitivities_NNS and_CC specificities_NNS of_IN the_DT dot_NN blot_NN ELISA_NP and_CC LA_NP test_NN were_VBD compared_VBN with_IN those_DT of_IN the_DT ELISA_NP by_IN using_VBG the_DT McNemar_NP test_NN ._SENT The_DT measures_NNS of_IN agreement_NN between_IN any_DT pair_NN of_IN these_DT three_CD tests_NNS were_VBD assessed_VBN by_IN use_NN of_IN the_DT kappa_NN statistic_NN ,_, which_WDT was_VBD interpreted_VBN as_IN the_DT chance_NN corrected_VBN proportional_JJ agreement_NN between_IN the_DT methods_NNS ._SENT A_DT P_NN value_NN of_IN <0.05_NN was_VBD considered_VBN significant_JJ ._SENT Specificities_NNS of_IN tests_NNS for_IN P._NP marneffei_NP ._SENT |_SYM Specificity_NN results_NNS for_IN the_DT dot_NN blot_NN ELISA_NP ,_, the_DT LA_NP test_NN ,_, and_CC the_DT ELISA_NP are_VBP presented_VBN in_IN Table_NP ._SENT All_DT strains_NNS of_IN P._NP marneffei_NP culture_NN supernatant_JJ ,_, from_IN both_DT yeast_NN and_CC hyphal_JJ forms_NNS ,_, gave_VBD positive_JJ results_NNS by_IN the_DT dot_NN blot_NN ELISA_NP as_IN well_RB as_RB by_IN the_DT LA_NP test_NN ._SENT In_IN the_DT LA_NP test_NN ,_, the_DT time_NN for_IN the_DT appearance_NN of_IN agglutination_NN for_IN yeast-form_NN whole-cell_NN culture_NN supernatants_NNS of_IN P._NP marneffei_NP (_( median_JJ ,_, 4_CD s_NNS [_SYM range_NN ,_, 3_CD to_TO 6_CD s_NN ]_SYM ;_: n_NN =_SYM 4_CD )_) was_VBD significantly_RB shorter_JJR than_IN that_IN for_IN culture_NN supernatants_NNS of_IN the_DT hyphal_JJ form_NN (_( median_JJ ,_, 7_CD s_NNS [_SYM range_NN ,_, 7_CD to_TO 15_CD s_NN ]_SYM ;_: n_NN =_SYM 3_LS )_) (_( P_NN =_SYM 0.031_CD )_) ._SENT The_DT lowest_JJS detection_NN limits_NNS for_IN P._NP marneffei_NP antigen_NN in_IN both_CC the_DT dot_NN blot_NN ELISA_NP and_CC the_DT LA_NP test_NN were_VBD 103_CD yeast_NN cells/ml_NN ._SENT Similar_JJ titration_NN results_NNS were_VBD found_VBN when_WRB either_DT PBS_NP or_CC urine_NN was_VBD used_VBN as_IN the_DT diluent_NN ._SENT These_DT findings_NNS were_VBD similar_JJ to_TO those_DT of_IN the_DT established_JJ ELISA_NP ._SENT However_RB ,_, the_DT ELISA_NP was_VBD more_RBR sensitive_JJ ;_: it_PP gave_VBD positive_JJ results_NNS at_IN 102_CD yeast_NN cells/ml_NN ._SENT All_PDT the_DT other_JJ fungal_JJ culture_NN supernatants_NNS gave_VBD negative_JJ results_NNS in_IN the_DT dot_NN blot_NN ELISA_NP ,_, the_DT LA_NP test_NN ,_, and_CC the_DT ELISA_NP up_RP to_TO concentrations_NNS of_IN 108_CD cells/ml_NN ._SENT All_DT bacterial_JJ strains_NNS except_IN S._NP aureus_NN were_VBD nonreactive_JJ in_IN these_DT tests_NNS ;_: S._NP aureus_NN gave_VBD positive_JJ results_NNS in_IN the_DT dot_NN blot_NN ELISA_NP and_CC ELISA_NP (_( but_CC not_RB the_DT LA_NP test_NN )_) ,_, but_CC only_RB at_IN a_DT concentration_NN of_IN 108_CD cells/ml_NN ._SENT Detection_NN of_IN P._NP marneffei_NP antigen_NN in_IN urine_NN by_IN dot_NN blot_NN ELISA_NP ._SENT |_SYM The_DT results_NNS of_IN the_DT dot_NN blot_NN ELISA_NP with_IN urine_NN from_IN patients_NNS with_IN penicilliosis_NN and_CC the_DT control_NN groups_NNS are_VBP given_VBN in_IN Table_NP ._SENT The_DT results_NNS were_VBD compared_VBN with_IN those_DT of_IN the_DT established_JJ ELISA_NP ._SENT Of_IN the_DT 37_CD HIV-positive_JJ patients_NNS with_IN culture-confirmed_JJ P._NP marneffei_NN infection_NN ,_, 35_CD (_( 94.6_CD %_NN )_) were_VBD positive_JJ for_IN P._NP marneffei_NP urinary_JJ antigen_NN by_IN the_DT dot_NN blot_NN ELISA_NP and_CC 36_CD (_( 97.3_CD %_NN )_) were_VBD positive_JJ by_IN the_DT ELISA_NP at_IN a_DT cutoff_NN titer_NN of_IN >=1:40_NN ._SENT All_DT 52_CD samples_NNS from_IN healthy_JJ volunteers_NNS were_VBD negative_JJ by_IN the_DT dot_NN blot_NN ELISA_NP ._SENT Of_IN the_DT 34_CD samples_NNS from_IN patients_NNS with_IN other_JJ fungal_JJ infections_NNS ,_, 2_CD (_( 5.9_CD %_NN )_) were_VBD positive_JJ by_IN the_DT dot_NN blot_NN ELISA_NP ._SENT False-positive_JJ results_NNS were_VBD also_RB found_VBN for_IN 2_CD (_( 1.2_CD %_NN )_) of_IN 168_CD urine_NN samples_NNS from_IN patients_NNS with_IN melioidosis_NN ,_, 1_CD (_( 8.3_CD %_NN )_) of_IN 12_CD urine_NN samples_NNS from_IN patients_NNS with_IN other_JJ bacterial_JJ septicemias_NNS ,_, 1_CD (_( 14.3_CD %_NN )_) of_IN 7_CD urine_NN samples_NNS from_IN patients_NNS with_IN other_JJ bacterial_JJ infections_NNS ,_, and_CC 2_CD (_( 7.4_CD %_NN )_) of_IN 27_CD subjects_NNS who_WP were_VBD culture_NN negative_JJ ._SENT Thus_RB ,_, false-positive_JJ results_NNS were_VBD found_VBN for_IN 8_CD (_( 2.7_CD %_NN )_) of_IN 300_CD control_NN urine_NN samples_NNS overall_JJ by_IN the_DT dot_NN blot_NN ELISA_NP ._SENT This_DT compares_VBZ with_IN 6_CD (_( 2_CD %_NN )_) of_IN 300_CD control_NN urine_NN samples_NNS that_WDT were_VBD positive_JJ by_IN ELISA_NP ._SENT Detection_NN of_IN urinary_JJ antigen_NN by_IN the_DT LA_NP test_NN ._SENT |_SYM All_DT 37_CD samples_NNS from_IN confirmed_VBN penicilliosis_NN patients_NNS were_VBD positive_JJ by_IN the_DT LA_NP test_NN ._SENT The_DT results_NNS are_VBP shown_VBN in_IN Table_NP ._SENT The_DT median_JJ time_NN to_TO agglutination_NN was_VBD 30_CD s_NNS (_( range_NN ,_, 15_CD to_TO 180_CD s_NNS )_) ;_: i.e._FW ,_, the_DT time_NN to_TO agglutination_NN was_VBD longer_JJR than_IN that_DT observed_VBN with_IN whole-cell_NN cultures_NNS of_IN P._NP marneffei_NP ._SENT All_DT except_IN 2_CD of_IN the_DT 300_CD control_NN urine_NN samples_NNS were_VBD negative_JJ ;_: these_DT 2_CD (_( 5.9_CD %_NN )_) samples_NNS were_VBD from_IN among_IN the_DT 34_CD patients_NNS with_IN other_JJ fungal_JJ infections_NNS (_( the_DT 2_CD samples_NNS were_VBD both_DT reactive_JJ by_IN the_DT dot_NN blot_NN ELISA_NP and_CC the_DT ELISA_NP ,_, and_CC both_DT patients_NNS were_VBD HIV_NP antibody_NN positive_NN )_) ._SENT Thus_RB ,_, false-positive_JJ results_NNS were_VBD found_VBN for_IN only_RB 2_CD (_( 0.7_CD %_NN )_) of_IN 300_CD control_NN urine_NN samples_NNS overall_JJ by_IN the_DT LA_NP test_NN ._SENT Only_RB one_CD urine_NN sample_NN (_( from_IN a_DT patient_NN in_IN the_DT "_`` other_JJ septicemia_NN "_'' group_NN )_) gave_VBD a_DT nonspecific_JJ reaction_NN ._SENT Diagnostic_JJ sensitivity_NN and_CC specificity_NN ._SENT |_SYM The_DT sensitivity_NN and_CC specificity_NN of_IN the_DT dot_NN blot_NN ELISA_NP ,_, the_DT ELISA_NP ,_, and_CC the_DT LA_NP test_NN are_VBP summarized_VBN in_IN Table_NP ._SENT By_IN using_VBG a_DT cutoff_NN titer_NN of_IN 1:40_CD in_IN the_DT ELISA_NP ,_, the_DT overall_JJ sensitivity_NN for_IN penicilliosis_NN was_VBD 97.3_CD %_NN and_CC the_DT specificity_NN ,_, using_VBG data_NNS for_IN all_DT control_NN groups_NNS ,_, was_VBD 98_CD %_NN (_( positive_JJ predictive_JJ value_NN [_SYM PPV_NP ]_SYM ,_, 85.7_CD %_NN ;_: negative_JJ predictive_JJ value_NN [_SYM NPV_NP ]_SYM ,_, 99.7_CD %_NN )_) ._SENT The_DT sensitivity_NN of_IN the_DT dot_NN blot_NN ELISA_NP was_VBD lower_JJR ,_, at_IN 94.6_CD %_NN ,_, with_IN a_DT specificity_NN of_IN 97.3_CD %_NN (_( PPV_NP ,_, 81.4_CD %_NN ;_: NPV_NP ,_, 99.3_CD %_NN )_) ._SENT The_DT sensitivity_NN and_CC specificity_NN of_IN the_DT LA_NP test_NN were_VBD 100_CD and_CC 99.3_CD %_NN ,_, respectively_RB (_( PPV_NP ,_, 94.9_CD %_NN ;_: NPV_NP ,_, 100_CD %_NN )_) ._SENT There_EX were_VBD no_DT significant_JJ differences_NNS between_IN the_DT three_CD tests_NNS (_( dot_NN blot_NN ELISA_NP versus_FW ELISA_NP ,_, P_NN =_SYM 0.99_CD ;_: LA_NP test_NN versus_IN ELISA_NP ,_, P_NN =_SYM 0.45_CD ;_: and_CC dot_VBP blot_VB ELISA_NP versus_CC LA_NP test_NN ,_, P_NN =_SYM 0.29_CD )_) ._SENT In_IN addition_NN ,_, there_EX was_VBD significant_JJ agreement_NN between_IN each_DT pair_NN of_IN tests_NNS (_( dot_NN blot_NN ELISA_NP versus_FW ELISA_NP ,_, kappa_NN =_SYM 0.825_CD and_CC P_NN <_SYM 0.001_CD ,_, LA_NP test_NN versus_IN ELISA_NP ,_, kappa_NN =_SYM 0.902_CD and_CC P_NN <_SYM 0.001_CD ,_, and_CC dot_VBP blot_VB ELISA_NP versus_CC LA_NP test_NN ,_, kappa_NN =_SYM 0.889_CD and_CC P_NN <_SYM 0.001_CD )_) ._SENT These_DT results_NNS indicate_VBP that_IN although_IN the_DT LA_NP test_NN achieved_VBD the_DT highest_JJS sensitivity_NN and_CC PPV_NP for_IN detection_NN of_IN P._NP marneffei_NP antigen_NN in_IN urine_NN ,_, there_EX is_VBZ little_JJ in_IN terms_NNS of_IN performance_NN from_IN which_WDT to_TO choose_VB among_IN the_DT three_CD tests_NNS for_IN the_DT diagnosis_NN of_IN penicilliosis_NN ._SENT TABLE_NN 1_CD |_SYM Reactivity_NN of_IN purified_VBN rabbit_NN anti-P_NN ._SENT marneffei_NP IgG_NP against_IN control_NN organisms_NNS in_IN dot_NN blot_NN ELISA_NP ,_, LA_NP test_NN ,_, and_CC ELISA_NP TABLE_NP 2_CD |_SYM Comparison_NN of_IN dot_NN blot_NN ELISA_NP ,_, LA_NP test_NN ,_, and_CC ELISA_NP for_IN detection_NN of_IN P._NP marneffei_NP antigen_NN in_IN urine_NN specimens_NNS TABLE_NP 3_CD |_SYM Sensitivity_NN and_CC specificity_NN of_IN P._NP marneffei_NP urinary_JJ antigen_NN detection_NN by_IN dot_NN blot_NN ELISA_NP ,_, LA_NP test_NN ,_, and_CC ELISA_NP Penicilliosis_NN is_VBZ now_RB recognized_VBN as_IN one_CD of_IN the_DT most_RBS important_JJ opportunistic_JJ infections_NNS in_IN AIDS_NP patients_NNS in_IN Thailand_NP ,_, affecting_VBG 6.8_CD %_NN of_IN AIDS_NP patients_NNS in_IN the_DT north_NN of_IN the_DT country_NN ._SENT At_IN present_NN ,_, the_DT diagnosis_NN of_IN P._NP marneffei_NP infection_NN relies_VBZ on_IN the_DT identification_NN of_IN yeast_NN cells_NNS in_IN smears_NNS of_IN skin_NN lesion_NN ,_, blood_NN ,_, or_CC bone_NN marrow_NN specimens_NNS ,_, but_CC there_EX may_MD be_VB confusion_NN with_IN histoplasmosis_NN or_CC disseminated_VBN cryptococcosis_NN ._SENT Culture_NN is_VBZ often_RB the_DT only_JJ way_NN to_TO confirm_VB the_DT diagnosis_NN ,_, particularly_RB if_IN characteristic_JJ skin_NN lesions_NNS are_VBP absent_JJ ,_, but_CC this_DT may_MD take_VB several_JJ days_NNS ._SENT Thus_RB ,_, a_DT rapid_JJ diagnostic_JJ or_CC confirmatory_JJ test_NN would_MD be_VB of_IN clinical_JJ value_NN ,_, and_CC its_PP$ results_NNS could_MD be_VB used_VBN to_TO direct_VB the_DT appropriate_JJ antifungal_JJ therapy_NN ._SENT Rapid_JJ identification_NN of_IN fungal_JJ pathogens_NNS ,_, once_RB isolated_VBN in_IN pure_JJ culture_NN ,_, can_MD be_VB achieved_VBN with_IN specific_JJ DNA_NN probes_NNS ,_, but_CC these_DT tests_NNS have_VBP not_RB yet_RB been_VBN applied_VBN to_TO clinical_JJ specimens_NNS for_IN rapid_JJ diagnosis_NN ._SENT There_EX have_VBP been_VBN few_JJ advances_NNS in_IN diagnostic_JJ tests_NNS for_IN penicilliosis_NN since_IN a_DT previous_JJ report_NN ._SENT Several_JJ specific_JJ protein_NN antigens_NNS of_IN P._NP marneffei_NNS have_VBP been_VBN identified_VBN to_TO be_VB immunologically_RB reactive_JJ in_IN Western_JJ blot_NN assays_NNS for_IN approximately_RB 50_CD %_NN of_IN serum_NN specimens_NNS from_IN patients_NNS with_IN penicilliosis_NN and_CC 20_CD %_NN of_IN serum_NN specimens_NNS from_IN patients_NNS with_IN cryptococcosis_NN or_CC candidiasis_NN ._SENT A_DT mannoprotein_NN antibody_NN ELISA_NP has_VBZ been_VBN reported_VBN to_TO be_VB positive_JJ for_IN 80_CD %_NN of_IN HIV-positive_JJ penicilliosis_NN patients_NNS ,_, but_CC serum_NN specimens_NNS from_IN patients_NNS with_IN other_JJ fungal_JJ infections_NNS were_VBD not_RB included_VBN in_IN that_DT study_NN ,_, and_CC there_EX have_VBP been_VBN no_DT reports_NNS of_IN prospective_JJ clinical_JJ evaluations_NNS ._SENT Thus_RB ,_, the_DT usefulness_NN of_IN antibody_NN tests_NNS for_IN diagnosis_NN of_IN penicilliosis_NN in_IN areas_NNS where_WRB penicilliosis_NN is_VBZ endemic_JJ remains_VBZ uncertain_JJ ._SENT Antigen_NN detection_NN tests_NNS may_MD be_VB more_RBR appropriate_JJ than_IN antibody_NN detection_NN tests_NNS for_IN the_DT diagnosis_NN of_IN penicilliosis_NN in_IN immunocompromised_JJ patients_NNS ,_, in_IN whom_WP antigen_NN loads_NNS are_VBP high_JJ and_CC antibody_NN responses_NNS may_MD be_VB muted_VBN ._SENT Detection_NN of_IN P._NP marneffei_NP antigen_NN also_RB suggests_VBZ active_JJ rather_RB than_IN past_JJ infection_NN ,_, which_WDT is_VBZ particularly_RB relevant_JJ in_IN an_DT area_NN of_IN endemicity_NN ._SENT A_DT fluorescent-antibody_NN test_NN for_IN the_DT tissue_NN form_NN of_IN P._NP marneffei_NP that_WDT uses_VBZ a_DT rabbit_NN polyclonal_JJ antibody_NN raised_VBN against_IN whole_JJ P._NP marneffei_NN yeast_NN cells_NNS has_VBZ been_VBN described_VBN ,_, as_RB has_VBZ an_DT LA_NP test_NN for_IN detection_NN of_IN P._NP marneffei_NP antigen_NN in_IN serum_NN and_CC urine_NN (_( this_DT was_VBD evaluated_VBN with_IN a_DT small_JJ number_NN of_IN patient_NN and_CC control_NN serum_NN samples_NNS ,_, and_CC only_RB two_CD urine_NN samples_NNS from_IN penicilliosis_NN patients_NNS were_VBD tested_VBN )_) ._SENT Prospective_JJ clinical_JJ evaluations_NNS of_IN these_DT tests_NNS have_VBP not_RB been_VBN reported_VBN ._SENT A_DT cell_NN wall_NN mannoprotein_NN antigen_NN has_VBZ been_VBN demonstrated_VBN in_IN the_DT serum_NN of_IN 65_CD %_NN of_IN 26_CD penicilliosis_NN patients_NNS ;_: the_DT sensitivity_NN was_VBD increased_VBN to_TO 88_CD %_NN if_IN this_DT test_NN was_VBD used_VBN in_IN conjunction_NN with_IN an_DT antibody_NN detection_NN test_NN ._SENT A_DT urinary_JJ antigen_NN detection_NN test_NN with_IN a_DT rabbit_NN IgG_NP antibody_NN developed_VBN for_IN diagnosis_NN of_IN H._NP capsulatum_NP var._NP capsulatum_NN infection_NN has_VBZ been_VBN reported_VBN to_TO give_VB positive_JJ results_NNS for_IN 17_CD of_IN 18_CD confirmed_VBD penicilliosis_NN patients_NNS ._SENT More_RBR recently_RB ,_, we_PP reported_VBD that_IN a_DT rabbit_NN polyclonal_JJ antibody_NN raised_VBN against_IN killed_VBN whole-fission-form_NN arthroconidia_NN of_IN P._NP marneffei_NP could_MD be_VB used_VBN to_TO quantify_VB urinary_JJ antigen_NN by_IN ELISA_NP ._SENT At_IN a_DT cutoff_NN titer_NN of_IN 1:40_CD ,_, this_DT urinary_JJ antigen_NN ELISA_NP had_VBD a_DT diagnostic_JJ sensitivity_NN of_IN 97_CD %_NN and_CC a_DT specificity_NN of_IN 98_CD %_NN ._SENT The_DT polyclonal_JJ rabbit_NN antibody_NN used_VBN previously_RB in_IN the_DT ELISA_NP was_VBD used_VBN in_IN the_DT present_JJ study_NN for_IN the_DT development_NN of_IN the_DT dot_NN blot_NN ELISA_NP and_CC the_DT LA_NP test_NN ._SENT Each_DT of_IN our_PP$ tests_NNS ,_, the_DT dot_NN blot_NN ELISA_NP ,_, the_DT ELISA_NP ,_, and_CC the_DT LA_NP test_NN ,_, appears_VBZ to_TO be_VB highly_RB sensitive_JJ and_CC specific_JJ ._SENT The_DT LA_NP test_NN detected_VBD antigen_NN in_IN all_DT 37_CD urine_NN specimens_NNS from_IN patients_NNS with_IN culture-confirmed_JJ penicilliosis_NN ,_, whereas_IN the_DT dot_NN blot_NN ELISA_NP and_CC ELISA_NP detected_VBD antigen_NN in_IN 35_CD and_CC 36_CD urine_NN specimens_NNS ,_, respectively_RB ._SENT The_DT two_CD specimens_NNS with_IN false-negative_JJ dot_NN blot_NN ELISA_NP results_NNS had_VBD ELISA_NP titers_NNS of_IN only_RB 1:40_CD (_( the_DT cutoff_NN titer_NN )_) ._SENT Of_IN the_DT remaining_VBG 35_CD dot_NN blot_NN ELISA-positive_JJ specimens_NNS ,_, 34_CD had_VBD ELISA_NP titers_NNS of_IN 1:320_CD or_CC greater_JJR ._SENT One_PP dot_VBP blot_VB ELISA-positive_JJ undiluted_JJ urine_NN specimen_NN had_VBD antigen_NN detectable_JJ only_RB by_IN ELISA_NP (_( the_DT patient_NN presented_VBD initially_RB with_IN disseminated_VBN cryptococcal_JJ infection_NN )_) ._SENT The_DT LA_NP test_NN was_VBD also_RB rapid_JJ ;_: agglutination_NN occurred_VBN in_IN all_DT 37_CD positive_JJ specimens_NNS by_IN 180_CD s_NNS (_( median_JJ ,_, 30_CD s_NNS )_) ._SENT Only_RB two_CD positive_JJ results_NNS were_VBD found_VBN among_IN 300_CD control_NN specimens_NNS ;_: these_DT specimens_NNS were_VBD positive_JJ by_IN all_DT three_CD tests_NNS ._SENT Both_DT specimens_NNS were_VBD from_IN HIV-positive_JJ patients_NNS with_IN cryptococcosis_NN ,_, and_CC we_PP cannot_MD exclude_VB the_DT possibility_NN that_IN they_PP were_VBD also_RB infected_VBN with_IN P._NP marneffei_NP ,_, although_IN we_PP were_VBD unable_JJ to_TO culture_VB it_PP from_IN suitable_JJ specimens_NNS ._SENT False-positive_JJ results_NNS by_IN the_DT dot_NN blot_NN ELISA_NP (_( eight_CD patients_NNS )_) were_VBD slightly_RB more_RBR common_JJ than_IN false-positive_JJ results_NNS by_IN the_DT ELISA_NP (_( six_CD patients_NNS )_) ._SENT Two_CD patients_NNS gave_VBD false-positive_JJ results_NNS by_IN both_CC the_DT dot_NN blot_NN ELISA_NP and_CC the_DT ELISA_NP ;_: one_CD of_IN these_DT patients_NNS was_VBD also_RB HIV_NP positive_NN and_CC presented_VBN with_IN a_DT Salmonella_NP septicemia_NN ,_, while_IN a_DT coliform_JJ organism_NN was_VBD cultured_VBN from_IN the_DT urine_NN of_IN the_DT other_JJ patient_NN (_( whose_WP$ HIV_NP infection_NN status_NN was_VBD unknown_JJ )_) ;_: again_RB ,_, we_PP are_VBP unable_JJ to_TO exclude_VB penicilliosis_NN in_IN these_DT patients_NNS ._SENT The_DT antigens_NNS detected_VBN by_IN the_DT polyclonal_JJ rabbit_NN antibody_NN remain_VBP to_TO be_VB characterized_VBN ._SENT However_RB ,_, it_PP is_VBZ evident_JJ from_IN our_PP$ studies_NNS that_DT detection_NN of_IN antigen_NN in_IN urine_NN with_IN this_DT antibody_NN is_VBZ highly_RB specific_JJ and_CC sensitive_JJ whether_IN the_DT antibody_NN is_VBZ used_VBN in_IN an_DT ELISA_NP ,_, a_DT dot_NN blot_NN ELISA_NP ,_, or_CC an_DT LA_NP test_NN ._SENT There_EX is_VBZ little_JJ in_IN terms_NNS of_IN performance_NN from_IN which_WDT to_TO choose_VB among_IN the_DT three_CD tests_NNS ._SENT However_RB ,_, the_DT LA_NP test_NN is_VBZ by_IN far_RB the_DT more_RBR preferable_JJ for_IN routine_JJ diagnostic_JJ use_NN :_: it_PP is_VBZ a_DT simple_JJ ,_, convenient_JJ ,_, rapid_JJ ,_, and_CC reliable_JJ method_NN for_IN detecting_VBG P._NP marneffei_NP antigenuria_NP ,_, which_WDT should_MD allow_VB its_PP$ widespread_JJ use_NN even_RB where_WRB laboratory_NN facilities_NNS are_VBP very_RB limited_VBN ._SENT The_DT ELISA_NP and_CC dot_NN blot_NN ELISA_NP do_VBP not_RB offer_VB any_DT advantages_NNS over_IN the_DT LA_NP test_NN and_CC are_VBP considerably_RB more_RBR laborious_JJ and_CC time-consuming_JJ ._SENT The_DT LA_NP test_NN reagent_NN can_MD be_VB readily_RB produced_VBN by_IN sensitizing_VBG latex_NN particles_NNS with_IN our_PP$ rabbit_NN polyclonal_JJ antibody_NN ,_, and_CC it_PP should_MD prove_VB useful_JJ as_IN a_DT diagnostic_JJ test_NN for_IN P._NP marneffei_NP infection_NN ._SENT It_PP should_MD therefore_RB be_VB developed_VBN further_RBR ._SENT We_PP also_RB hope_VBP to_TO evaluate_VB this_DT test_NN for_IN the_DT detection_NN of_IN antigenemia_NN and_CC use_VB it_PP to_TO assess_VB responses_NNS to_TO antifungal_JJ therapy_NN in_IN a_DT study_NN of_IN serial_JJ urinary_JJ antigen_NN testing_NN during_IN treatment_NN and_CC subsequent_JJ follow-up_NN ._SENT 